{
    "relation": [
        [
            "Citing Patent",
            "US7829120",
            "US7988998 *",
            "US8221792",
            "US8372432",
            "US8377453",
            "US8394408",
            "US8597681",
            "US8658631",
            "US8668929",
            "US8722087",
            "US8741885",
            "US8858963",
            "US8916588",
            "US8927010",
            "US9023389",
            "US9028868",
            "US9050335",
            "DE102013009114A1",
            "WO2010099508A1",
            "WO2014205228A1 *"
        ],
        [
            "Filing date",
            "Sep 11, 2006",
            "Apr 22, 2005",
            "Jul 7, 2006",
            "Dec 22, 2009",
            "Mar 11, 2009",
            "Jan 27, 2012",
            "Jun 22, 2011",
            "May 16, 2012",
            "Jun 21, 2012",
            "Aug 18, 2008",
            "May 16, 2012",
            "May 16, 2012",
            "Mar 31, 2014",
            "Mar 31, 2014",
            "Jan 5, 2015",
            "Mar 23, 2012",
            "May 16, 2012",
            "May 29, 2013",
            "Feb 26, 2010",
            "Jun 19, 2014"
        ],
        [
            "Publication date",
            "Nov 9, 2010",
            "Aug 2, 2011",
            "Jul 17, 2012",
            "Feb 12, 2013",
            "Feb 19, 2013",
            "Mar 12, 2013",
            "Dec 3, 2013",
            "Feb 25, 2014",
            "Mar 11, 2014",
            "May 13, 2014",
            "Jun 3, 2014",
            "Oct 14, 2014",
            "Dec 23, 2014",
            "Jan 6, 2015",
            "May 5, 2015",
            "May 12, 2015",
            "Jun 9, 2015",
            "Dec 4, 2014",
            "Sep 2, 2010",
            "Dec 24, 2014"
        ],
        [
            "Applicant",
            "Labopharm Inc.",
            "Labopharm Inc.",
            "Farnam Companies, Inc.",
            "Depomed, Inc.",
            "Depomed, Inc.",
            "Depomed, Inc.",
            "Mallinckrodt Llc",
            "Mallinckrodt Llc",
            "Depomed, Inc.",
            "Purdue Pharma L.P.",
            "Mallinckrodt Llc",
            "Mallinckrodt Llc",
            "Ironshore Pharmaceuticals & Development, Inc.",
            "Ironshore Pharmaceuticals & Development, Inc.",
            "Ironshore Pharmaceuticals & Development, Inc.",
            "Ironshore Pharmaceuticals & Development, Inc.",
            "Mallinckrodt Llc",
            "Franz Gerstheimer",
            "Theraquest Biosciences, Inc.",
            "Orbis Biosciences, Inc."
        ],
        [
            "Title",
            "Trazodone composition for once a day administration",
            "Sustained-release tramadol formulations with 24-hour efficacy",
            "Sustained release pharmaceutical compositions for highly water soluble drugs",
            "Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic",
            "Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic",
            "Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic",
            "Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans",
            "Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia",
            "Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic",
            "Titration dosing regimen for controlled release tramadol",
            "Gastric retentive extended release pharmaceutical compositions",
            "Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia",
            "Methods for treatment of attention deficit hyperactivity disorder",
            "Compositions for treatment of attention deficit hyperactivity disorder",
            "Compositions for treatment of attention deficit hyperactivity disorder",
            "Methods and compositions for treatment of attention deficit disorder",
            "Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia",
            "Pharmazeutische Zusammensetzung zur \ufffdberwindung von Metabolisierungsproblemen",
            "Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use",
            "Tramadol particle formulations and methods"
        ]
    ],
    "pageTitle": "Patent US7074430 - Controlled release tramadol tramadol formulation - Google Patents",
    "title": "",
    "url": "http://www.google.com/patents/US7074430?dq=%235,519,867",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988048.90/warc/CC-MAIN-20150728002308-00296-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 475489459,
    "recordOffset": 475440618,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{66775=Suitable water soluble polymers are PEG with molecular weights in the range 1000 to 6000., 65049=We have also found that particles containing tramadol or a salt thereof produced by a melt processing as described in application PCT/SE93/00225 and the process described and claimed in our prior unpublished UK application No. 9324045.5 filed on 23 Nov. 1993 as well as the process described herein are particularly useful for processing into the form of tablets., 24280=This application is a continuation of U.S. patent application Ser. No. 08/677,798, filed Jul. 10, 1996; now U.S. Pat. No. 6,254,887 which is a continuation of U.S. patent application Ser. No. 08/241,129, filed May 10, 1994 (now U.S. Pat. No. 5,591,452).}",
    "textBeforeTable": "Patent Citations in comparison to the administration of a commercial preparation of Tramadol drops 100 mg. FIG. 2 In a trial involving five healthy male volunteers the plasma profile resulting from single dose administrations of the above tablet are shown in 77 24 73 20 67 16 60 12 55 10 50 8 44 6 37 4 32 3 27 2 20 1 % TRAMADOL HCl RELEASED HOURS AFTER START OF TEST The resulting tablets were then assessed by the",
    "textAfterTable": "US4533562 Apr 19, 1984 Aug 6, 1985 Sankyo Company, Limited Method of preparing coated solid preparations US4613619 Feb 22, 1985 Sep 23, 1986 Akzo N.V. Anti-arrhythmic amino-alcohols US4708874 Mar 10, 1986 Nov 24, 1987 Rijksuniversiteit Groningen Devices for the controlled release of active substances, as well as process for the preparation thereof US4797410 Apr 16, 1987 Jan 10, 1989 Miles Inc. Suppression of withdrawal symptoms in opioid-induced tolerance or dependence US4801458 Jun 23, 1986 Jan 31, 1989 Teijin Limited Sustained release pharmaceutical plaster US4801460 Apr 6, 1987 Jan 31, 1989 Basf Aktiengesellschaft Preparation of solid pharmaceutical forms US4828836 May 19, 1987 May 9, 1989 Euroceltique S.A. Controlled release pharmaceutical composition US4834984 May 19, 1987 May 30, 1989 Euroceltique S.A. Controlled release dihydrocodeine composition US4834985 May 19, 1987 May 30, 1989 Euroceltique S.A. Controlled release pharmaceutical",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}